Lv3
380 积分 2022-02-15 加入
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced/Metastatic NSCLC
9小时前
待确认
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
9小时前
已完结
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
20天前
已完结
肿瘤治疗性mRNA疫苗非临床评价的考虑
2个月前
已完结
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2个月前
已完结
RNA vaccines for cancer: Principles to practice
3个月前
已完结
Cancer mRNA vaccines: clinical advances and future opportunities
3个月前
已完结
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
6个月前
已完结
Novel mouse model for carcinoembryonic antigen-based therapy
7个月前
已完结
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study
7个月前
已完结
皖公网安备34019202002308
